Skip to main content
. 2016 Jan 21;6:19626. doi: 10.1038/srep19626

Figure 5. TubA (25 mg/kg) increased fibroblast growth factor-21 (FGF-21) levels in the ischemic cortex and striatum on Days 1 and 3 after ischemia.

Figure 5

Middle cerebral artery occlusion (MCAO) reduced protein and mRNA levels of FGF-21 in the ischemic cortex (A) and striatum (B) on Days 1 and 3 after ischemia. FGF-21 mRNA levels were also markedly decreased in the ischemic cortex (C) and striatum (D) on Day 3. TubA significantly restored FGF-21 protein and mRNA levels on Day 3 in the cortex. FGF-2 and FGF-19 mRNA levels were not affected by TubA treatment in the ischemic cortex on Day 3 (E). β-Klotho mRNA levels were robustly decreased in the ischemic cortex on Day 3, and this decrease was markedly reversed by TubA treatment (F). #P < 0.05, ##P < 0.01, ###P < 0.001 compared with sham control; *P < 0.05, ***P < 0.001 compared with MCAO group; n = 6 per group.